• LinkedIn

The Business of Biofabrication

  • News
  • Perspectives
  • Learn

R.D. Solorzano

  • Why Vertex Is Staying the Course on VX-880 (Zimislecel) — Even as Novo Nordisk Pulls Back
    October 14, 2025

    Why Vertex Is Staying the Course on VX-880 (Zimislecel) — Even as Novo Nordisk Pulls Back

    R.D. Solorzano
  • Mytos Launches Automated CDMO to Scale Regenerative Cell Therapies
    October 13, 2025

    Mytos Launches Automated CDMO to Scale Regenerative Cell Therapies

    R.D. Solorzano
  • L’Oréal and AMKbiotech Partner to Unlock Next-Generation Insights in Skin Biology with High-Plex Imaging
    October 13, 2025

    L’Oréal and AMKbiotech Partner to Unlock Next-Generation Insights in Skin Biology with High-Plex Imaging

    R.D. Solorzano
  • JETT: Connecting Innovators with the Joint Chem Bio Enterprise
    October 10, 2025

    JETT: Connecting Innovators with the Joint Chem Bio Enterprise

    R.D. Solorzano
  • Vensana Capital Unveils Vensana Innovation, Welcomes Dr. Thomas Tu as Venture Partner
    October 8, 2025

    Vensana Capital Unveils Vensana Innovation, Welcomes Dr. Thomas Tu as Venture Partner

    R.D. Solorzano
  • Tides Medical – APLICOR 3D’s  New Personalized 3D Bioprinted Skin Graft Available for Patients at Singing River Health System
    October 7, 2025

    Tides Medical – APLICOR 3D’s New Personalized 3D Bioprinted Skin Graft Available for Patients at Singing River Health System

    R.D. Solorzano
  • NIH Launches Nation’s First Dedicated Organoid Development Center
    October 3, 2025

    NIH Launches Nation’s First Dedicated Organoid Development Center

    R.D. Solorzano
  • CUTISS Secures CHF 56 Million Series C to Advance Phase 3 Skin-Tissue Therapy
    September 29, 2025

    CUTISS Secures CHF 56 Million Series C to Advance Phase 3 Skin-Tissue Therapy

    R.D. Solorzano
  • MIT and Polimi Develop Low-Cost AI Monitoring System to Improve 3D Bioprinting of Engineered Tissues
    September 25, 2025

    MIT and Polimi Develop Low-Cost AI Monitoring System to Improve 3D Bioprinting of Engineered Tissues

    R.D. Solorzano
  • Prellis Biologics and Eli Lilly Sign Multi-Target Antibody Discovery Agreement
    September 23, 2025

    Prellis Biologics and Eli Lilly Sign Multi-Target Antibody Discovery Agreement

    R.D. Solorzano
Previous Page
1 2 3 4 … 12
Next Page

Archives

To make sense of, stay update on, and learn about
the business of biofabrication

Subscribe

2024 All Rights Reserved

  • Subscribe Subscribed
    • The Business of Biofabrication
    • Already have a WordPress.com account? Log in now.
    • The Business of Biofabrication
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar